Back to search

Peptide record

TPDB12584

Antibacterial Anticancer Antifungal Hemolysis Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB12584
Antibacterial Anticancer Antifungal Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 Antifungipept CAFPdb PD_Hemolysis
standard
No
A 13-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FLGALWNVAKRVF
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C75H113N19O15
DCEQHIMPSTY
ALFV
1520.84
11.49
2
0
9
+2
-0.28
0.923
120.00
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
5500
3.62
1
Residue Composition
number
2
A
1
R
1
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
2
L
1
K
0
M
2
F
0
P
0
S
0
T
1
W
0
Y
2
V
Amino Acid Distribution
A: 2 R: 1 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 2 K: 1 M: 0 F: 2 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 2
Chemical Descriptors
13 reviewed residue count
C75H113N19O15 sequence-only estimate (linear, free termini)
1520.84 sequence-only estimate (linear, free termini)
11.49 sequence-only estimate (linear, free termini)
+2 sequence-only estimate (linear, free termini)
-0.28 sequence-only estimate (linear, free termini)
0.923 sequence-only estimate (linear, free termini)
Evidence Records 4 records
Evidence 1 Activity

Activity

0% Hemolysis
Toxicity
3.1 µM
Hemolytic Cytotoxic
0% Hemolysis | 3.1 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Repurposing the scorpion venom peptide VmCT1 into an active peptide against Gram-negative ESKAPE pathogens. | Bioorg Chem | 2019
Evidence 2 Activity

Activity

50% Hemolysis
Toxicity
12.5 µM
Hemolytic Cytotoxic
50% Hemolysis | 12.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Repurposing the scorpion venom peptide VmCT1 into an active peptide against Gram-negative ESKAPE pathogens. | Bioorg Chem | 2019
Evidence 3 Activity

Activity

% Hemolysis
Toxicity
25 %
Hemolytic
Hemolytic_activity: [Ref.31212183] 25% hemolysis at 6.3 µmol/L, 50% hemolysis at 12.5 µmol/L, 70% hemolysis at 25 µmol/L, 90% hemolysis at 500 µmol/L for human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Bioorg Chem. 2019 Jun 8 90:103038. doi: 10.1016/j.bioorg.2019.103038.
Evidence 4 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis